Pfizer COVID-19 Vaccine Trial Protocol https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf
Pfizer's COVID-19 Clinical Trial Phase 1/2/3 in clinicaltrials.gov https://clinicaltrials.gov/ct2/show/study/NCT04368728
Trial start date April 29, 2020. Estimated completion date May 2, 2023
Offical Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Scedule of Activities leading out to 24 months (Page 18); https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf
Study Population -- People included or excluded from trials (Page 40)
Moderna COVID-19 Vaccine Trial Protocol https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf
Moderna's COVID-19 Clinical Trial Phase 3 in clinicaltrials.gov https://clinicaltrials.gov/ct2/show/study/NCT04470427
Trial start date July 27, 2020. Estimated completion date October 27, 2022
Offical Title: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
Table 14: Schedule of Events (Vaccination Phase, Day 1 – Day 57) Page 104 https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf
Table 15: Schedule of Events (Surveillance Phase, Day 64 – Day 394) Page 108
Table 16: Schedule of Events (Surveillance Phase, Day 401 – Day 759) Page 112
Study Population -- People included or excluded from trials (Page 43)